CHRS: Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end
The company has fully transitioned to innovative oncology, with LOQTORZI driving revenue growth and funding a robust pipeline. Key assets tagmokitug and casdozokitug are advancing in trials, with major data updates expected in October and year-end, supported by a strong cash position.Based on Coher…